Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


C.R. Bard

This article was originally published in The Gray Sheet

Executive Summary

Firm expects to receive ambulatory payment classification (APC) code for reimbursement of its EndoCinch endoscopic suturing system, indicated for treatment of gastroesophageal reflux disease (GERD), in July or October of this year, company reports during an April 17 quarterly earnings call. The APC code was originally filed in May 2000. Separately, the firm's Memotherm endoscopic biliary stent system gains FDA market go-ahead for treatment of malignant biliary obstructions. The condition affects roughly 30,000 people in the U.S. Bard's first quarter sales were up 6% to $284.8 mil. and net income advanced 5.4% to $33.2 mil



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts